A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
About this study
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Tested
- ALN-4324, Placebo
- Sponsor
- Alnylam Pharmaceuticals
Who can join
- Age
- 18 to 65 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Maximum age: 65 years
- Study condition: Type 2 Diabetes Mellitus (T2DM)
- Is an adult patient with a confirmed diagnosis of T2DM
- Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2
- Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
- Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i)
Exclusion 3
- Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
- Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods
- Note: other protocol defined inclusion/exclusion criteria apply
Where
1 site, 1 recruiting
Clinical Trial Site
Chula Vista, California, United States
Contact
-
Alnylam Clinical Trial Information Line
1-877-ALNYLAM clinicaltrials@alnylam.com
-
Alnylam Clinical Trial Information Line
1-877-256-9526 clinicaltrials@alnylam.com
Potential match only. Final eligibility is determined by the study team.